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Background: Barrier dysfunction is recognized as a pathogenic factor in ulcerative colitis (UC) and irritable bowel syndrome (IBS), but it is 
unclear to what extent the factors related to barrier dysfunction are disease-specific. The aim of this study was to compare these aspects in UC 
patients in remission, IBS patients, and healthy controls (HCs).
Methods: Colonic biopsies were collected from 13 patients with UC in remission, 15 patients with IBS-mixed, and 15 HCs. Ulcerative colitis 
patients had recently been treated for relapse, and biopsies were taken from earlier inflamed areas. Biopsies were mounted in Ussing chambers 
for measurements of intestinal paracellular permeability to 51chromium (Cr)-ethylenediaminetetraacetic acid (EDTA). In addition, biopsies were 
analyzed for mast cells and eosinophils by histological procedures, and plasma tumor necrosis factor (TNF)-α was assessed by ELISA. 
Results: Ussing chamber experiments revealed an increased 51Cr-EDTA permeability in UC and IBS (P < 0.05). The 51Cr-EDTA permeability 
was higher in UC compared with IBS (P < 0.005). There were increased numbers of mucosal mast cells and eosinophils in UC and IBS and more 
eosinophils in UC compared with IBS (P < 0.05). Also, increased extracellular granule content was found in UC compared with HCs (P < 0.05). 
The 51Cr-EDTA permeability correlated significantly with eosinophils in all groups. Plasma TNF-α concentration was higher in UC compared 
with IBS and HCs (P < 0.0005). 
Conclusions: Results indicate a more permeable intestinal epithelium in inactive UC and IBS compared with HCs. Ulcerative colitis patients, 
even during remission, demonstrate a leakier barrier compared with IBS. Both eosinophil numbers and activation state might be involved in the 
increased barrier function seen in UC patients in remission.
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INTRODUCTION
Ulcerative colitis (UC) and irritable bowel syndrome 
(IBS) are 2 chronic gastrointestinal (GI) entities with incom-
pletely understood pathophysiology. Ulcerative colitis is an in-
flammatory bowel disease (IBD) characterized by intermittent 
flares of bloody stools and increased stool frequency. Unlike 
IBS, UC features macroscopic mucosal inflammation during 
active disease. Irritable bowel syndrome is one of the most 
common functional bowel disorders characterized by recurring 
abdominal pain and associated with disturbed bowel habits.1 
In terms of mucosal barrier function studies, the majority 
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of abnormalities found in UC and IBS are based on the com-
parison of healthy controls (HCs) with either UC patients2–4 
or IBS patients.5–7 However, to evaluate if  the barrier function 
disturbances demonstrated in UC and IBS are disease-specific 
or generalizable for both disorders, control studies are needed. 
Today, there are only few such studies directly comparing bar-
rier function of UC and IBS.8, 9 It is well known that there also 
exists a clinical overlap between UC and IBS because patients 
with UC in remission often report IBS-like symptoms that do 
not necessarily correspond to a low-grade inflammation, even 
though increased levels of pro-inflammatory cytokines have 
been reported.10
A low-grade mucosal inflammation is often present in the 
colon and ileum of IBS patients, characterized by mast cells, T 
cells, and pro-inflammatory cytokines.11, 12 Ahn et al13 showed 
that patients with diarrhea-predominant IBS (IBS-D) had sig-
nificantly more colonic mast cells and T cells in relation to HCs 
but had similar counts when compared with UC patients in re-
mission. Nevertheless, colonic tissue from IBS-D patients had 
significantly fewer immune cells than the colon from patients 
with mildly activated UC.
A barrier dysfunction is well recognized as an important 
pathogenic factor in UC,2–4 and an impaired barrier function 
has become evident also in IBS.5–7 There are few studies com-
paring gut barrier function in IBS and UC in remission. Gecse 
et al8 found that intestinal permeability was elevated in patients 
with IBS-D and inactive UC compared with HCs by measuring 
24-hour urine excretion of orally administered 51Chromium 
(Cr)-ethylenediaminetetraacetic acid (EDTA). In another study 
by Vivinus-Nébot et al,9 both IBS (all subtypes) and quiescent 
UC patients with IBS-like symptoms showed higher paracel-
lular permeability compared with HCs, as measured using fluo-
rescein isothiocyanate-sulfonic acid in Ussing chambers, but 
they found no difference between HCs and quiescent UC pa-
tients with no IBS-like symptoms. To our knowledge, there is to 
date no study directly comparing the colonic barrier function 
between IBS, UC in remission, and HCs by using biopsies and 
permeability markers in Ussing chambers—a gold standard 
technique for the assessment of intestinal permeability ex vivo.
There is substantial evidence for an elevated number and 
increased degranulation of mast cells and secretion of medi-
ators in UC14–16 and IBS.5, 17, 18 In addition, some studies have 
implicated mast cells in the regulation of intestinal permea-
bility.19–21 Our group previously found an increased number 
of mast cells and their activation in the colonic mucosa in IBS 
compared with HCs and an increased permeability in colonic 
biopsies of IBS patients, which was significantly diminished 
after stabilizing the mast cells with ketotifen.5 In addition, we 
recently demonstrated higher amounts of mast cells in the co-
lonic mucosa of UC and Crohn’s disease patients compared 
with HCs.16 Together, this indicates that mast cells have an im-
portant role in both IBS and IBD, including UC, and are also 
important regulators of barrier function. The intestinal mucosa 
contains moderate amounts of active eosinophils.22 However, 
it is known that the numbers of activated eosinophils are in-
creased in patients with active and inactive UC.23 Furthermore, 
the numbers have shown to be higher in the mucosa of inac-
tive UC compared with the inflamed mucosa,23 suggesting that 
eosinophils may play diverse roles in the pathophysiology of 
IBD—both pro-inflammatory and mediating tissue repair. 
Moreover, a close interaction between eosinophils and mast 
cells, potentially leading to a disrupted mucosal barrier and in-
creased permeability, has been demonstrated in IBD.24, 25 For 
IBS, colon studies have shown inconsistent results with both 
increased26, 27 and unaltered eosinophil counts.28
A better knowledge about the differences between IBS 
and UC in remission are important for a deeper understanding 
of the disease-specific barrier function disturbances in these 
disorders. The present study was designed to search for simi-
larities and differences in epithelial barrier function and related 
immune cells between UC in remission and IBS. Colonic bi-
opsies from patients with inactive UC, IBS, and HC patients 
were mounted in Ussing chambers to assess paracellular per-
meability. Mucosal mast cells and eosinophils were quantified; 
intracellular and extracellular tryptase and eosinophil cationic 
protein (ECP), respectively, were analyzed; and plasma levels of 
tumor necrosis factor (TNF)-α were measured.
MATERIALS AND METHODS
Participants
The material included 13 patients with inactive 
UC, 15 patients with IBS, and 15 HCs, recruited from 
the Gastroenterology Department, University Hospital, 
Linköping, Sweden. Inclusion criteria for the UC group was 
clinical and endoscopic remission and treatment for relapse 
within the last year. Biopsies were taken from the earlier in-
flamed area. Inclusion criteria for the IBS group was that pa-
tients were classified in the IBS-mixed (IBS-M) subgroup based 
on the predominant stool consistency according to the Rome 
III questionnaire.29 The HCs were recruited by advertisement, 
and inclusion criteria was that patients had no medical his-
tory of  chronic GI symptoms or disorders and no medication 
intake. Exclusion criteria for all groups included metabolic 
or neurological disorders. The Committee of  Human Ethics, 
Linköping, approved the study, and all subjects gave their 
written informed consent.
Collection of Biological Samples
A flexible sigmoidoscopy was performed in all partici-
pants, and colonic biopsies were taken from the sigmoideum, 
rectosigmoidal junction, or rectum. All biopsies were taken 
with forceps without a central lance and directly put in ice-
cold oxygenated Krebs buffer (115 mM NaCl, 1.25 mM CaCl2, 
1.2 mM MgCl2, 2 mM KH2PO4, and 25 mM NaHCO3, pH 7.35). 
Before sigmoidoscopy, venous blood samples were collected in 
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EDTA-treated tubes, blood was centrifuged at 3400g for 15 
minutes in 4°C, and plasma was redrawn and frozen in −80°C 
until analysis of TNF-α concentration.
Ussing Chamber Experiments
Colonic biopsies were mounted in Ussing chambers 
(Harvard Apparatus Inc., Holliston, MA, USA) as previously de-
scribed.30 After 40 minutes of equilibration, 34 µCi/mL of the para-
cellular probe 51Cr-EDTA (Perkin Elmer, MA, USA) was added to 
the mucosal side of each chamber. Serosal samples were collected at 
0, 60, and 120 minutes, and 51Cr-EDTA passage was measured by 
gamma-counting (1282 Compugamma, Sweden). The 51Cr-EDTA 
permeability was calculated during the 60 to 120 minute period, 
and results are presented as Papp (apparent permeability coeffi-
cient; cm/s ×10-6). The transepithelial potential difference (PD) and 
the transepithelial resistance (TER) across the tissues were moni-
tored throughout the experiments to ensure tissue viability.
Measurements of TNF-α Concentration in Plasma
An ultrasensitive human TNF-α ELISA kit was used ac-
cording to the manufacturer’s instructions (Invitrogen, Thermo 
Fisher Scientific, Lund,  Sweden). Undiluted plasma, positive 
and negative controls, and standard points were added in du-
plicates. Absorbance was measured at 450 nm in VERSAmax 
Tunable Microplate Reader (Molecular Devices, CA, USA) 
using Softmax pro 5 (Molecular Devices).
Staining of Mast Cells and Eosinophils in the 
Colonic Mucosa
Immediately after collection, colonic biopsies were fixed 
in 4% paraformaldehyde in phosphate buffered saline for 24 
hours at 4°C and further embedded in paraffin and sectioned 
at 5 µm. Upon use, slides were hydrated according to standard 
procedures.
Mast cells
Sections were incubated with background sniper 
(Histolab, Gothenburg,  Sweden) for 5 minutes. Slides were 
rinsed and incubated over night at 4°C with mouse monoclonal-
antihuman mast cell tryptase 1:200 (Santa Cruz, CA, USA). 
Slides were rinsed and incubated with 1:400 secondary an-
tibody Alexa Fluor 594-conjugated rabbit-antimouse (Life 
Technologies, Stockholm, Sweden) for 1 hour at room tempera-
ture. Slides were rinsed and mounted with Prolong Gold-DAPI 
(Life Technologies).
Eosinophils
Slides were incubated in Harris hematoxylin (Casa 
Alvarez, Madrid, Spain) for 4 minutes. After brief  rinsing in tap 
water, slides were immersed in 1% hydrochloric alcohol for 10 
seconds, re-immersed in tap water, and immersed in tap water 
with 2 to 3 ammonia drops for 1 minute. Finally, slides were 
incubated in eosin (Casa Alvarez) for 1 minute and mounted 
with Pertex mounting media (Histolab).
Quantification of Mast Cells and Eosinophils
The total number of mucosal mast cells and eosino-
phils was quantified in a blinded fashion by 2 independent re-
searchers in a Nikon E800 fluorescence microscope connected 
to software NIS elements (Nikon Instruments Inc. Tokyo, 
Japan). The number of cells positive for tryptase or eosin were 
quantified manually at 400x magnification, and negative con-
trols were included in all experiments. A minimum of 8 areas/
sections was counted. Every area had the same size, and only 
areas that were covered completely by the biopsy were used. 
The mean value for each section was estimated for mast cell 
tryptase expression or eosin and a median value of the number 
of mast cells and eosinophils from patients with UC, IBS, and 
HCs, respectively.
Distribution of mast cell tryptase and eosinophil-
ECP and cell ultrastructure
To study the granule distribution and activation levels 
of eosinophils and mast cells, biopsies from randomly selected 
subjects, 4 UC patients in remission, 4 IBS-M patients and 4 
HCs, were processed for immunofluorescence and evaluated 
with confocal microscopy. Mast cells were identified using 
antihuman tryptase following the protocol described previously 
for mast cell quantification. Similarly, eosinophils were iden-
tified with antihuman ECP 1:200 (Diagnostic Development, 
Uppsala, Sweden), an eosinophil activation marker. Slides were 
stained using the same protocol described previously for mast 
cells quantification, with an additional antigen retrieval step 
with citrate buffer at 60°C for 30 minutes. One transversal sec-
tion/individual was used for each staining, and negative controls 
were included in all experiments. From 8 to 14 images of single 
mast cells or eosinophils (single when possible) were acquired 
with LSM800 Zeiss Inverted Confocal with a 60X oil immersion 
objective. Images were processed in ImageJ Fiji software (NIH, 
Bethseda, MD), followed by the analysis with Cell Profiler 2.2.0 
software. Nuclei signal was used, together with tryptase or ECP 
signal, to delimit and segment the cell limits of mast cell and 
eosinophils, respectively. All the granules detected inside those 
limits were defined as intracellular; the granules localized out-
side the cellular limits were defined as extracellular content 
and interpreted as an indicative of degranulation levels. After 
threshold, the average of integrated intensity per cell and the ex-
tracellular content surrounding the cell were measured. Finally, 
a median value was calculated from all the averages to create a 
median of intensity expressed with arbitrary units (AUs).
To further identify and illustrate signs of mast cell and 
eosinophil activation, biopsies were processed for transmission 
electron microscopy (TEM). Biopsies from all groups were fixed 
in 2.5% glutaraldehyde in 0.1 M phosphate buffer for 24 to 72 
hours, postfixed, dehydrated, and further processed according 
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to standard protocols for TEM. Representative photographs 
of mast cells and eosinophils were achieved using a Hitachi 
H-1400 electron microscope.
Statistical Analysis
Data were analyzed using the GraphPad Prism 7 Software 
(GraphPad Software Inc., CA, USA). All data, except electro-
physiology data, were confirmed as normally distributed and 
given as mean ±SEM. Comparisons between these groups were 
done with Student t or ANOVA test. Electrophysiology data 
(TER) was given as median (25th to 75th percentile), and com-
parisons between groups were done with the Mann-Whitney U 
test when there were 2 groups or the Kruskal-Wallis test fol-
lowed by the Dunn multiple comparisons test when there were 
multiple groups. Differences with P  <  0.05 were considered 
significant. Correlation testing was done with 2-tailed Pearson 
correlation test. Influence on the results of different parameters 
related to patient’s characteristics (as indicated in Table 1) was 
analyzed with the Mann-Whitney U and Spearman correlation 
tests (continuous variable and stratification).
RESULTS
Patients and HCs
The material included 13 patients with inactive UC, 
15 patients with IBS-M, and 15 HCs (Table  1). All UC pa-
tients were in clinical and endoscopic remission (Full Mayo 
score ≤2).31 At the day of endoscopy, UC patients graded the 
presence of abdominal pain for the previous day, (none, mild, 
moderate, or severe). Four patients reported mild abdominal 
pain, and 1 reported moderate abdominal pain. All IBS patients 
were classified in the IBS-M subgroup and had moderate-severe 
symptoms with median symptom severity score (SSS)32 of 343 
(range 167–462), and none of the patients related the onset of 
their symptoms to infectious gastroenteritis. Measurements 
of plasma-C-reactive protein (p-CRP) showed that all UC pa-
tients had p-CRP <10 mg/mL (median 2.1, range 0.2–7.1) when 
biopsies were achieved. Analyses showed that biopsy location 
(rectum/rectosigmoidal junction/sigmoideum) had no signifi-
cant impact on any of the results.
Decreased TER in UC and IBS Compared 
With HCs
Ussing chamber experiments showed a stable PD after 
equilibration in all biopsies, indicating a good tissue viability 
throughout the experiments (data not shown) and ensuring that 
differences observed were not due to differences in viability be-
tween biopsies.
Ussing chamber experiments revealed a lower TER in bi-
opsies from both UC and IBS patients compared with HCs al-
ready at time 0 (P < 0.05; Fig. 1A). Transepithelial resistance 
remained lower after both 60 and 120 minutes from start, both 
in UC (60 min, 22.1 [18.2–26.1] ohm × cm2, P < 0.05; 120 min, 
20.1 [16.9–23.0], P < 0.005) and IBS (60 min, 21.8 [18.2–27.2], 
P < 0.05; 120 min, 20.6 [17.7–26.5], P < 0.05) compared with HCs 
(60 min, 27.0 [23.0–31.9]; 120 min, 25.4 [23.3–29.7]). Changes of 
TER over time, 0 to 120 minutes, are shown in Figs. 1B–D.
Increased Paracellular Permeability in UC 
and IBS
Permeability to 51Cr-EDTA over time (60–120 min) was 
higher in both UC (P < 0.0005) and IBS (P < 0.05) compared 
TABLE 1. Patient Characteristics of the 13 Patients with UC in Remission and 15 Patients with IBS-mixed and 15 
Healthy Controls Included in the Study
UC IBS HCs
Age, median (range) 36 (21–72) years 31 (19–52) years 27 (21–61) years
Sex 7 women, 6 men 15 women 11 women, 4 men
Biopsy location Sigmoideum (n = 7) Sigmoideum (n = 15) Sigmoideum (n = 10)
Rectum (n = 6)  Rectosigmoidal junction (n = 5) 
Endoscopic Mayo score 0 (n = 12) 0 (n = 15) 0 (n = 15)
1 (n = 1)   
Anti-inflammatory medication 5-ASA (n = 12) None None
Steroids (n = 1)   
Infliximab (n = 1)   
Azathioprine (n = 3)   
Allergy/smoking Pollen (n = 2) None None
 Pollen & fur (n = 1)   
 Smoking (n = 2)   
Biopsies were taken in October-December that is outside pollen season in Sweden.
 Inflamm Bowel Dis • Volume 26, Number 7, July 2020
978
Katinios et al
with HCs. Moreover, paracellular permeability was signifi-
cantly higher in UC biopsies compared with IBS (P < 0.005; 
Fig. 2). A higher paracellular permeability was not correlated 
to a higher grade of abdominal pain in UC patients (r = 0.34, 
P = 0.27), but notably, the highest permeability of 51Cr-EDTA 
(4.3  cm/s ×10-6) was recorded in the single UC patient who 
graded the presence of abdominal pain as moderate. In line 
with this, there was no correlation between 51Cr-EDTA per-
meability and IBS SSS (r  =  0.15, P  =  0.31); however, the 2 
IBS patients displaying the 2 highest SSS values displayed the 
2 highest 51Cr-EDTA permeability measurements (1.75 and 
1.95 cm/s ×10-6, respectively).
FIGURE 1. A, Transepithelial resistance (TER) measured at start, 0 min, in colonic biopsies from patients with ulcerative colitis in remission, irritable 
bowel syndrome, and healthy controls. Bars represent median (25th–75th percentile). B–D, Changes of TER over time in UC (B), IBS (C), and HCs 
(D). Graphs show median TER values and the variability at each time point (25th–75th percentile). Comparisons between 2 groups were done with 
Mann-Whitney U test. *P < 0.05.
FIGURE 2. Paracellular permeability to 51Chromium (Cr)-EDTA in colonic 
biopsies from patients with ulcerative colitis in remission, irritable 
bowel syndrome, and healthy controls. Biopsies were mounted in 
Ussing chambers, and permeability to 51Cr-EDTA was measured over 
the 60–120 min period after start. Bars represent median (25th–75th 
percentile), and comparisons between 2 groups were done with Mann-
Whitney U test. *P < 0.05, **P < 0.005, ***P < 0.0005.
FIGURE 3. Concentrations of TNF-α in plasma from patients with ulcer-
ative colitis in remission, irritable bowel syndrome, and healthy con-
trols. Bars represent median (25th–75th percentile), and comparisons 
between 2 groups were done with Mann-Whitney U test. **P < 0.005, 
***P < 0.0005.
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Increased TNF-α in Plasma of UC Patients in 
Remission
ELISA revealed higher TNF-α levels in plasma of UC 
compared with both IBS (P < 0.005) and HCs (P < 0.0005), 
whereas there was no significant difference between IBS and 
HCs (Fig.  3). There was no significant correlation between 
plasma TNF-α concentrations and 51Cr-EDTA permeability.
Increased Number of Mucosal Mast Cells in UC 
and IBS Compared With HCs
Colonic biopsies from both UC and IBS patients showed 
increased number of mast cells compared with HCs (P < 0.05; 
Fig.  4A). However, there was no difference in the number 
of mast cells between UC (144.7  ±  19.2 cells/mm2) and IBS 
(132.1 ± 12.7 cells/mm2). Representative photomicrographs of 
tryptase-positive cells are shown in Figure 4B–D.
The majority of both UC (85%) and IBS (85%) had 
higher mast cell numbers compared with the mean of HCs. 
This indicates recruitment of mast cell progenitors from the cir-
culation into tissues of almost all IBS and UC patients.
Increased Number of Mucosal Eosinophils in UC 
Compared with IBS and HCs
Eosin staining revealed an increased number of eosino-
phils in both UC (P < 0.0005) and IBS (P < 0.005) compared 
with HCs (Fig. 5A). In contrast to mast cells, the number of 
eosinophils was significantly elevated in UC mucosa compared 
with IBS (P  <  0.0005). Representative photographs of cells 
identified as eosinophils are shown in Figure 5B–D. Eosinophils 
were often found just beneath the epithelial cell border; in UC, 
they were often found in clusters, as illustrated in Figure 5B. 
When comparing microscopy results patient by patient, it was 
shown that 100% of the UC patients and approximately 69% 
of the IBS patients had elevated eosinophil numbers compared 
with the mean of HCs. This indicates that a mucosal immune 
activation seems to be present in almost all patients.
Decreased intracellular tryptase in mast cells in UC
Intracellular and extracellular tryptase were quanti-
fied in single mast cells with confocal microscopy in biopsies 
from 4 UC patients (mean ±SD, 39.2 ± 9.2 years; 2 women), 
4 patients with IBS-M (30.8  ±  6.2  years; 4 women) and 4 
HCs (36 ± 7.9 years; 4 women). Intracellular measurements 
showed significant decreased tryptase content in mast cells 
of  UC patients compared with IBS (P < 0.05), but no differ-
ence was found in extracellular tryptase surrounding the cells 
(Fig. 6A).
Ultrastructural visual analysis identified signs of activa-
tion in mast cells from all samples, with higher heterogeneity 
in granular electrodensity and pseudopodes in the UC and IBS 
groups. Representative images are shown in Figure 6A.
FIGURE 4. A, Mucosal mast cells quantified by immunofluorescence 
in colonic biopsies from patients with ulcerative colitis in remission, 
irritable bowel syndrome, and healthy controls. B–D, Representative 
photographs of mast cell tryptase-positive cells (red, arrows) in the 
colonic mucosa of UC, IBS, and HC, respectively. Blue, nuclei staining 
by DAPI. Magnification 600X. Bars represent median (25th–75th per-
centile), and comparisons between 2 groups were done with Mann-
Whitney U test. **P < 0.005.
FIGURE 5. A, Graph showing mucosal eosinophils quantified by he-
matoxylin and eosin staining in colonic biopsies from patients with 
ulcerative colitis in remission, irritable bowel syndrome, and healthy 
controls. B–D, Photographs illustrating cells positive for eosin (arrows) 
in the colonic mucosa of UC, IBS, and HC, respectively. Magnification 
600X. Bars represent median (25th–75th percentile), and comparisons 
between 2 groups were done with Mann-Whitney U test. **P < 0.005, 
***P < 0.0005.
 Inflamm Bowel Dis • Volume 26, Number 7, July 2020
980
Katinios et al
FIGURE 6. Mast cell tryptase and eosinophil cationic protein (ECP) distribution in colonic biopsies from patients with ulcerative colitis in re-
mission, irritable bowel syndrome, and healthy controls. A, Quantification of intracellular/extracellular tryptase. Representative images of mast 
cells with identification of plasma cell membrane (white line), and tryptase located at intracellular (red) and extracellular (green) compartments. 
Ultrastructural analysis identifies partial degranulation of cytoplasmic granules (white arrow) in UC and IBS, indicative of activation, and a more 
stable phenotype in HC. B, Quantification of intracellular/extracellular ECP. Representative images of eosinophils with identification of plasma cell 
membrane (white line) and ECP located at intracellular (blue) and extracellular (pink) compartments. Ultrastructural analysis identifies partial de-
granulation of some cytoplasmic granules (white arrow) in UC and IBS, indicative of activation, and a more stable phenotype in HC. Quantification 
was done in 600X confocal images and expressed in arbitrary units. Bars represent median (25th–75th percentile), and comparisons were done with 
Mann-Whitney U test. *P < 0.05.
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Increased extracellular ECP in eosinophils in UC
Intracellular and extracellular ECP were quantified in 
single or eosinophils (a few clustered) in biopsies from patients 
with UC, IBS-M, and HC patients as indicated for mast cells. 
Even though intracellular ECP was not significantly different 
among groups, measurements showed increased extracellular 
ECP content in UC compared with HCs (P < 0.05; Fig. 6B).
Ultrastructural visual analysis of eosinophils showed an 
activated profile, with larger cytoplasmic granules in the UC 
group and partial degranulation of some cytoplasmic granules 
in UC and IBS groups as compared with HCs. Representative 
images are shown in Figure 6B.
Increased Paracellular Permeability Correlated 
to Number of Eosinophils
Correlation analysis of the measured parameters (TER, 
51Cr-EDTA permeability, mast cells, eosinophils, and plasma 
TNF-α concentrations) showed significant associations between 
paracellular permeability to 51Cr-EDTA and the number of eo-
sinophils in all groups: UC (r = 0.60, P < 0.05), IBS (r = 0.60, 
P < 0.05), and HCs (r = 0.63, P < 0.05) (Fig. 7A–C). However, 
no significant correlation was found between 51Cr-EDTA and 
the number of mast cells in any of the groups. Interestingly in 
UC patients, the number of mast cells was negatively correlated 
to the number of eosinophils (r = −0.73, P < 0.05; Fig. 7D). 
In HCs, there was a correlation between 51Cr-EDTA permea-
bility and TNF-α concentrations in plasma (r = 0.66, P < 0.05), 
though no significant correlations could be found in UC or IBS 
patients. Transepithelial resistance did not correlate with any of 
the other parameters (data not shown).
DISCUSSION
In this study, we showed that intestinal paracellular per-
meability was increased in both patients with inactive UC and 
IBS-M patients and that this increase was more evident in UC 
patients in remission in comparison with IBS-M patients. In ad-
dition, both inactive UC and IBS-M patients had significantly 
more mucosal mast cells and eosinophils than HCs, but only the 
number of eosinophils was significantly higher in UC in remis-
sion compared with IBS-M. Also, a significantly increased level 
of eosinophil degranulation, identified by higher amounts of 
extracellular ECP, could only be observed in UC. Furthermore, 
there was a significant positive correlation between eosinophil 
numbers and paracellular permeability to 51Cr-EDTA in all 
groups.
There is a realization that among other factors such as 
low-grade inflammation and genetic susceptibility, increased in-
testinal permeability also contributes to the pathophysiology of 
both IBS5–7 and UC.2–4 Moreover, it is known that a great per-
centage of patients with quiescent UC present IBS symptoms.33 
Our findings suggest that increased paracellular permeability 
might be a pathophysiological feature typical for both diseases. 
The electrophysiological measurements monitored throughout 
the Ussing chamber experiments demonstrated a lower TER 
in both UC and IBS biopsies as compared with HCs. This dif-
ference was detected from the start of experiments, suggesting 
structural changes in the integrity of the paracellular pathways. 
Ussing experiments further showed an increased paracellular 
permeability in both UC and IBS compared with HCs. This 
is in line with a previous study,8 showing an increased colonic 
permeability to orally administrated 51Cr-EDTA measured by 
24-hour urine excretion in both inactive UC and IBS-D com-
pared with HCs. Interestingly, the increase in permeability was 
correlated to stool frequency in IBS patients—but not in UC 
patients. We previously showed25 an increased transcellular 
passage but an unaltered paracellular permeability in biopsies 
from quiescent UC patients. However, these patients were in 
deep remission and had not had a relapse in several years, in 
comparison with the UC patients of the present study.
There was a higher number of mucosal mast cells in co-
lonic biopsies of both UC patients in remission and IBS-M 
patients in remission compared with HCs, as revealed by immu-
nofluorescence. The fact that the amount of mast cells seems to 
follow the same pattern both in inactive UC and IBS could in-
dicate that mast cells are a contributing factor to the increased 
paracellular permeability and, therefore, to the pathogenesis 
of these diseases, as is also shown previously.14 Though, there 
was neither a correlation between 51Cr-EDTA permeability 
and mast cell quantity nor a difference in mast cell numbers 
between UC and IBS, which indicates that mast cell amounts 
may not be responsible for the increased paracellular perme-
ability observed in UC compared with IBS. It might be that 
despite an unaltered number, there could be a difference in the 
granular content or activation status of the mast cells. Even 
though our results showed similar release of tryptase in both 
IBS and UC compared with HCs, it could still be a difference 
in granular content. There is a different mucosal environment 
that is of higher inflammatory degree in UC compared with 
IBS and HCs.18 Mast cells adapt their granular content to ex-
ternal factors; therefore, it would be of interest in future studies 
to identify which mediators are differentially produced in each 
entity. Previously, it was shown that the content of mast cells 
differs not only between healthy controls and IBD but also be-
tween UC and CD patients.34 Furthermore, Lloyd et al showed 
already in 1975 that there was a marked degranulation of intes-
tinal mast cells in CD compared with healthy controls.35 This 
was confirmed later on by Dvorak et al who described in more 
detail, using transmission electron microscopy, an enhanced de-
granulation of intestinal mast cells in patients with both CD36 
and UC.37 Other studies showed similar results in both CD and 
UC, using antibody specific immunohistochemistry against 
human mast cell markers tryptase and chymase.38
In the present study, histological staining with eosin re-
vealed significantly more eosinophils in both inactive UC and 
IBS-M colonic biopsies compared with HCs. Interestingly, the 
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number of eosinophils was significantly elevated in UC com-
pared with IBS, and degranulation analysis revealed signif-
icantly more degranulated eosinophils in UC compared with 
both IBS-M and HCs. Moreover, when looking at the data, it 
was indicated that the number of eosinophils seemed to corre-
late to the extracellular ECP levels in UC patients. Even though 
there were too few subjects to draw any conclusion, this pre-
liminary observation might suggest that the function of ECP 
is the key to the role of eosinophils. In line with this, Bystrom 
et al39 previously reported that ECP levels in patients with other 
conditions such as asthma, atopic dermatitis, lung disease, and 
various autoimmune conditions robustly correlated with the 
number of eosinophils present.
The reason for the increased number of eosinophils might 
be due to a higher recruitment of eosinophils during UC com-
pared with IBS. During active bowel inflammation, eosinophils 
are known to migrate to the GI tract in response to chemokines 
(eg, RANTES and eotaxin, both constitutively expressed 
throughout the gut). Eotaxin binds to the CCR-3 receptor on 
eosinophils, which is required for their homing to the GI tract.40 
It is, however, known that other cytokines are needed as well, 
among them interleukin (IL)-4, IL-5, IL-13 and TNF-α, which 
all increase the circulating number of eosinophils and prime 
them to enhance their response to eotaxin.40 Pro-inflammatory 
cytokines are known to be elevated during active disease com-
pared with inactive disease; 41 however, during both active and 
inactive phases of UC, significant levels of eotaxin has been 
reported in serum.42 It might be that, compared with IBS, there 
is a different cytokine milieu in the mucosa of patients with 
UC—even during remission—with somewhat enhanced levels 
of cytokines promoting the recruitment of eosinophils. The 
eotaxin CCL11 and IL-5 were increased in both active and 
inactive UC, and CCL11 was positively correlated to eosino-
phil numbers,43 supporting its contribution to eosinophil re-
cruitment. Moreover, Carlson et al44 showed increased release 
of eosinophil granule proteins in the noninflamed mucosa of 
patients with UC compared with controls, and Lampinen et al 
showed more activated eosinophils in the colon of inactive UC 
patients compared with active disease patients.23 Further, the 
early activation marker CD69 showed to be more expressed in 
inactive UC compared with active,45 and in addition, monocyte 
chemotactic factor‐4 and IL-33, known to activate human eo-
sinophils, were increased compared with controls in both active 
and inactive UC.45 These findings indicate eosinophil activity in 
the noninflamed colon, which could refer to the cytokines in the 
microenvironment. In addition, there might be other stimulus 
FIGURE 7. A–C, The correlation between eosinophil numbers and paracellular permeability to 51Chromium (Cr)-EDTA in colonic biopsies from pa-
tients with inactive ulcerative colitis (A), patients with irritable bowel syndrome (B), and healthy controls (C). The correlation between the number 
of eosinophils and mast cells in colonic biopsies from ulcerative colitis patients is illustrated (D). Correlation testing was done with 2-tailed Pearson 
correlation test.
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of eosinophil recruitment and activation present during remis-
sion; however, this needs to be further investigated.
An interesting observation was that eosinophils ap-
peared to concentrate just beneath the epithelium, and in UC, 
they were often found in clusters. In contrast, mast cells were 
more seldom found this close to the epithelial cell lining—and 
especially not in UC. One might speculate that the proximity 
of clustered eosinophils and the epithelial barrier could con-
tribute to increased permeability in UC. Eosinophil quantity 
was positively correlated to paracellular permeability in all 
groups, which is noteworthy because no correlation could be 
found between 51Cr-EDTA permeability and mast cells. This 
might be interpreted at first that the eosinophil number could 
have a higher impact on paracellular permeability than mast 
cells in the colonic mucosa. However, it could also be inferred 
that the increased amount and/or activation of eosinophils 
give rise to an enhanced secretion of corticotropin-releasing 
hormone (CRH), for example.24 As we previously described,25 
CRH can activate mast cells, and upon activation, mast cells 
start secreting a wide variety of bioactive mediators such as 
TNF-α, IL-3, IL-4, IL-5, IL-16, and IFNγ. Several of these me-
diators have effects on mucosal barrier function (eg, chymase, 
tryptase,46 IFNγ, and TNF-α).47 In this study, TNF-α levels 
were higher in plasma of UC patients compared with both IBS 
and HC patients. This, together with the correlation observed 
between paracellular permeability and eosinophil numbers, 
suggests an indirect involvement of mast cells, even though the 
effect on the barrier might be due to activation state rather than 
amount of mast cells.
One of the HCs had a very high number of eosinophils, 
146 cells/mm2, in comparison with the mean of HCs that was 
25.8 cells/mm2. This HC did not report any allergies, use of 
nonsteroidal anti-inflammatory drugs, or any other known 
diseases that could otherwise explain the enhanced eosinophil 
count.48 However, there could be a nonsymptomatic parasite 
infection49 or disease (eg, vasculitis),50 where eosinophils are in-
volved, of which the HC was not aware. Colonic eosinophilia 
is known to be caused by conditions such as allergies, parasitic 
infections, or drugs, and it is also a hallmark of IBD and eosin-
ophilic colitis.50, 51 In the present study, the presence or absence 
of allergies did not have any impact on any of the results; how-
ever, we do not have enough data to confidently exclude other 
conditions, as mentioned previously, that could influence the 
results as far as colon eosinophils are concerned.
Surprisingly, we found that the number of mast cells 
was negatively correlated to the number of eosinophils in UC 
in remission. This could be partly explained by ongoing treat-
ment with aminosalicylate (5-ASA) in the UC patients, as it has 
been shown (at least in IBS patients) that this treatment causes 
downregulation of mast cells.52 To our knowledge, data on the 
effect of 5-ASA on mast cells in UC are lacking; however, it 
seems reasonable to extrapolate the results of the previous study 
also to UC patients in remission. Whether 5-ASA could cause 
proportional increase of mucosal eosinophils is not known, al-
though several cases of 5-ASA–induced eosinophilic disorders 
have been described.53 The specific increase in eosinophils seen 
in UC is probably related to other factors, as well. For example, 
it could be speculated that 5-ASA can have effects on cell mat-
uration and progenitors. In contrast to our findings, in asthma 
and eosinophilic esophagitis, the levels of eosinophils and 
mast cells generally mirror each other.54 However, 5-ASA treat-
ment is generally not used in these conditions. In addition, our 
finding of a negative correlation between eosinophils and mast 
cells in UC might seem contradictory to our previous data25 re-
garding eosinophils secreting CRH, which activates mast cells 
to secrete mediators affecting the barrier. Our degranulation 
analyses showed no difference in extracellular tryptase in UC. 
This could either indicate that eosinophils have a more promi-
nent role compared with mast cells in UC barrier dysfunction 
or that the 5-ASA treatment drastically downregulates mast cell 
activation levels. Further studies are needed to understand the 
mechanism behind this.
Our findings of significantly higher TNF-α levels in UC 
plasma compared with IBS and HC—and comparable TNF-α 
levels in IBS and HCs—are consistent with previous studies55 
and in line with common knowledge that IBS does not seem 
to be a TNF-driven disease, in contrast to UC. There was no 
correlation between TNF-α levels in plasma and paracellular 
permeability in UC or IBS patients; however, a correlation was 
found in HCs. This might simply be explained by the fact that 
the levels of 51Cr-EDTA permeability, and especially TNF-α, 
are overall low in healthy controls which might give rise to the 
observed correlation between them.
In conclusion, our findings indicate a more permeable 
mucosa in patients with inactive UC and patients with mod-
erate to severe IBS compared with HCs. Ulcerative colitis pa-
tients, even during remission, display a leakier mucosal barrier 
compared with IBS, where eosinophils might be involved. 
Results further suggest a generalizable association between eo-
sinophils and paracellular permeability; however, because of 
the cross-sectional design of the study, we were not able to dem-
onstrate causality. This was also true for patients with IBS and 
HCs. The present results contribute to a better understanding 
of colonic paracellular permeability in patients with UC in re-
mission and IBS, though more studies are needed to confirm 
this in a larger material.
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